Johnson & Johnson Stock Performance
Johnson & Johnson shares traded at $273.20, reflecting a modest intraday decline of 0.38% per SID market data. Over the trailing twelve months, JNJ has delivered a gain of 34.38%, significantly outpacing its historically defensive profile characterized by a beta of just 0.349. On a shorter horizon, the stock has added 3.95% over the past month and 7.35% over the past three months, demonstrating sustained upward momentum. Technical indicators confirm this bullish trend positioning, with the current price sitting above both the 50-day moving average of $265.48 and the 200-day moving average of $248.36, according to Massive/Polygon data. The 14-day relative strength index registers at 61.6, indicating moderate bullish momentum without entering overbought territory. Average daily trading volume stands at approximately 8.82 million shares, supporting adequate liquidity for institutional participation. The company maintains a market capitalization of approximately $505.78 billion.
Johnson & Johnson Valuation Analysis
Johnson & Johnson currently trades at a price-to-earnings ratio of 20.30, positioning it within a moderate valuation range for the Healthcare sector, per SID market data. The PEG ratio stands at 1.91, suggesting the stock is trading slightly above fair value when earnings growth expectations are factored into the assessment. The company's price-to-book ratio of 6.43 reflects substantial intangible asset value inherent in its diversified pharmaceutical and medical technology portfolio, according to SEC filings. On the income return front, JNJ offers a dividend yield of approximately 2.45%, consistent with its long-standing reputation as a reliable income-generating holding. This yield provides a meaningful total return component alongside capital appreciation. The valuation metrics collectively indicate that the market assigns a premium to Johnson & Johnson's defensive qualities, consistent revenue streams, and diversified healthcare business model that spans pharmaceuticals, medical devices, and consumer health segments following its Kenvue separation.
Smart Money Activity for JNJ
Johnson & Johnson's composite smart money score registers at 50 out of 100, generating a neutral signal per SID market data. The institutional component scores a perfect 25 out of 25, reflecting strong conviction and sustained accumulation by large fund managers. In contrast, the insider trading score sits at 8.7 out of 25, reflecting mixed sentiment among company executives and directors. According to SEC Form 4 filings, there have been 16 insider transactions over the past 90 days, comprising 7 purchases and 9 sales, indicating a slight lean toward disposition activity. The dark pool score of 9.5 out of 25 suggests below-average off-exchange block trading activity relative to historical norms. Congressional trading activity scores 7.0 out of 25, indicating limited notable positioning by members of Congress, per 13F institutional filings and congressional disclosure records. The divergence between maximum institutional conviction and more modest insider and dark pool readings creates the overall neutral composite assessment, suggesting no dominant directional bias from sophisticated market participants at current price levels.
Johnson & Johnson Earnings Outlook
Johnson & Johnson has demonstrated consistent earnings execution across recent quarters, beating analyst estimates in three of the last four reporting periods, according to company earnings reports. The most recent quarter posted earnings per share of $2.59 against a consensus estimate of $2.53, representing a positive surprise of $0.06. The prior quarter delivered $2.90 versus an estimate of $2.85, a $0.05 beat. The quarter ending April 2026 saw EPS of $2.70 compared to the $2.67 estimate, a narrower $0.03 upside surprise. The sole miss occurred in January 2026, when JNJ reported $2.46 per share against expectations of $2.47, a marginal shortfall of $0.01, per analyst estimates. The sequential quarterly earnings trajectory from $2.46 to $2.70 to $2.90 reflects a positive growth trend. This pattern of modest but reliable beats underscores management's tendency toward conservative guidance and disciplined operational delivery.
Wall Street Analyst Ratings for JNJ
Wall Street consensus on Johnson & Johnson remains firmly constructive, with recent analyst actions uniformly maintaining positive ratings, per SID consensus data. In mid-October 2026, Wells Fargo reiterated its Overweight rating on two separate occasions, underscoring sustained conviction in the company's trajectory. Morgan Stanley also maintained its Overweight designation on October 15, 2026, according to Wall Street analyst reports. Additionally, both Leerink Partners and RBC Capital reiterated Outperform ratings on October 14, 2026, reflecting broad agreement among healthcare-focused research teams regarding JNJ's favorable positioning. Notably, all five of the most recent analyst actions represent rating reiterations rather than upgrades or downgrades, suggesting that the current bullish thesis is well-established and stable. No analyst in the recent coverage cycle has issued a downgrade or underweight recommendation. The consistency across multiple independent research franchises, including both bulge-bracket and specialty healthcare firms, signals a durable positive consensus view on the stock's fundamental outlook.
